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Summary Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia) is a Gram-
negative bacillus increasingly associated with serious nosocomial infections. Here, we describe a
30-year-old male patient who developed meningitis associated with this organism after several
neurosurgical procedures. A review of the literature revealed only 15 previous reports. Most cases
were associated with neurosurgical procedures. Antimicrobial therapy is complicated by multiple
drug resistanceof theorganism,and trimethoprim—sulfamethoxazole is the recommendedagent for
treatment.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Stenotrophomonas maltophilia (formerly Xanthomonas mal-
tophilia) is a Gram-negative, non-fermentative bacillus that is
ubiquitous in the environment.1 It is increasingly recognized
as a cause of serious infections in hospitalized patients.2—9
These infections are particularly common in patients who are
immunocompromised due to underlying illness. Meningitis
secondary to S. maltophilia has rarely been described. We
report a patient who developed meningitis, and review 15
previously described cases from the literature.
The case
A 30-year-old man was admitted to our neurosurgery inten-
sive care unit (ICU). He had undergone surgery twice at* Corresponding author. Tel.: +90 312 3175817.
E-mail address: yemisenmucahit@hotmail.com (M. Yemisen).
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doi:10.1016/j.ijid.2008.03.028another hospital for subdural hematoma and left parietal
contusion following a car accident. On admission to our clinic
the patient was unconscious, pupils were anisocoric, and his
response to pain was extensor. Assuming a cerebral hernia-
tion, the right temporoparietal hematoma was emptied with
a craniotomy.
Two days after surgery, the patient had a fever of 38.9 8C.
The laboratory findings on the same day were as follows:
white blood cell (WBC) count 22.3  109/l, C-reactive pro-
tein (CRP) 161 mg/dl (normal value<0.5 mg/dl), hemoglobin
11 mg/dl, hematocrit 34%, platelet count 145  109/l, urea
15 mg/dl, and creatinine 1.1 mg/dl. Cultures were obtained
and vancomycin 2  1 g and meropenem 3  1 g were
initiated empirically. We could not count the number of cells
in the cerebrospinal fluid (CSF) because of the cerebral
hemorrhage. The patient remained febrile, and on the third
day of treatment CSF culture yielded a positive signal. Gram-
negative bacilli were seen on Gram stain of the CSF culture.
On the following day, the Gram-negative bacilli were identi-
fied as S. maltophilia by conventional procedures. The strainPublished by Elsevier Ltd. All rights reserved.
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ciprofloxacin. We confirmed the result as S. maltophilia by
mini API system (BioMe´rieux). Other cultures did not yield
meaningful results. Treatment was switched to TMP—SMX
(trimethoprim 15 mg/kg) and ciprofloxacin 2  400 mg ther-
apy on the fourth day of meropenem and vancomycin treat-
ment, while the patient was still febrile.
On the third day of new combination therapy, his fever had
subsided to 37.4 8C, and the acute phase results were as
follows: WBC 16.4  109/l and CRP 71 mg/dl. On the fourth
day of therapy we obtained CSF for control culture, but it
yielded no positive result. At the end of two weeks, the
patient was conscious, afebrile, and discharged from the ICU.
Discussion
S. maltophilia, a Gram-negative rod, was first identified in
1958 by Hugh and Ryschenkow.1 Although S. maltophilia is a
rare cause of community-acquired infections, it is increasingly
recognized as an emerging cause of hospital-acquired infec-
tion, particularly among severely debilitated or immunosup-
pressed patients.2 S. maltophilia can cause a wide variety of
infections, including bacteremia, endocarditis, pneumonia,
pyelonephritis, cellulitis, and meningitis.3 Treatment ofTable 1 Details of patients with meningitis caused by Stenotrop
Case (Ref.) Age/sex Comorbidity
Patrick et al. (5) 70 years/M COPD
Denis et al. (6)
Case 1 8 months/M None
Case 2 13 months/F None
Trump et al. (7) 55 years/F Breast CA/CN
metastatis
Sarvamangala Devi et al. (8) 7 days/M Prematurity
Muder et al. (9) 65 years/F Intraventricul
hemorrhage
Girijaratnakumari et al. (10) 28 years/F Primary brain
Nguyen and Muder (11) 64 years/F Meningioma
Papadakis et al. (12)
Case 1 36 years/F Melanoma/
CNS metastat
Case 2 41 years/M CNS primary
lymphoma
Platsouka et al. (2) 42 years/M Cholesteatom
Lo et al. (13) 4 days/F Prematurity
Caylan et al. (14) 52 years/M Subarachnoid
hemorrhage
Spencer and Baron (15) 31 years/F Chronic sinusi
Libanore et al. (16) 49 years/M None
Present case 30 years/M Subarachnoid
hemorrhage
COPD, chronic obstructive pulmonary disease; M, male; F, female; CA
sulfamethoxazole.patients infected with S. maltophilia is generally complicated
because of high resistance to multiple antibiotics.4
Meningitis due to S. maltophilia is rarely seen, and there
are only 15 cases reported in the literature (Table 1). Menin-
gitis developed after a neurosurgical procedure in nine of
these 15 patients, and six were community-acquired.2,5—16
Four patients were children and the infection source in three
of them was community. Three patients died despite medical
therapy, but none of them received appropriate antibiotics.
Our case was also a nosocomial meningitis, and probably
acquired during the neurosurgical procedures.
Caylan et al.,14 reported the risk factors predisposing for
S. maltophiliameningitis, as prematurity, neurosurgical pro-
cedures (especially shunts or drains), intracranial hemor-
rhage, and malignancy. Carbapenem treatment has also
been suggested as a risk factor for infection/colonization
with S. maltophilia.17 Risk factors for our patient were
parallel to these reports: neurosurgical procedure applica-
tion and carbapenem use.
S. maltophilia is resistant to several antibiotics used
empirically for nosocomial infections. Inducible beta-lacta-
mase activity (including L1 metallo-b-lactamase and L2
serine-b-lactamase), efflux mechanism, aminoglycosidemod-
ifying enzyme activity, biofilm formation, and production ofhomonas maltophilia
Origin Therapy Outcome
Community Sulfadimidine,
chloramphenicol
Recovered
Community Ampicillin,
colistin
Died
Community Sulfadoxine,
chloramphenicol
Recovered
S Nosocomial Chloramphenicol,
gentamicin
Died
Community None Died
ar Nosocomial TMP—SMX Recovered
tumor Nosocomial Ciprofloxacin Recovered
Nosocomial TMP—SMX,
gentamicin
Recovered
is
Nosocomial TMP—SMX,
ceftazidime
Recovered
Nosocomial TMP—SMX,
amikacin
Recovered
a Nosocomial TMP—SMX,
ceftazidime
Recovered
Nosocomial Ciprofloxacin Recovered
Nosocomial TMP—SMX Recovered
tis Community TMP—SMX Recovered
Community Ceftazidime,
xamikacin
Recovered
Nosocomial TMP—SMX,
ciprofloxacin
Recovered
, cancer; CNS, central nervous system; TMP—SMX, trimethoprim—
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tance to multiple antibiotics.18 Nicodemo and Paez18 sug-
gested TMP—SMX as the empirical choice for clinically
suspected S. maltophilia infections and as the treatment of
choice for culture-proven infections by this agent. In the
reported cases, TMP—SMXwas the agentmost used. Our strain
was resistant to imipenem, meropenem, amikacin, ceftazi-
dime, piperacillin/tazobactam, and ampicillin/sulbactamand
sensitive to TMP—SMX and ciprofloxacin. There is not much
information in the literatureoncombination therapyagainst S.
maltophilia. Zelenitsky et al.19 reported that TMP—SMX com-
bined with other antimicrobial agents, such as ceftazidime,
produced a net bacterial kill and provided significant benefit
over monotherapy. We also used TMP—SMX and combined it
with ciprofloxacin for our patient.
In conclusion, S. maltophilia is an emerging pathogen for
nosocomial infections. Meningitis due to S. maltophilia is rare
and experience is limited. Physicians must be alert to S.
maltophilia, especially in the case of meningitis that devel-
ops after a neurosurgical procedure that does not respond to
empirical treatment. When S. maltophilia is obtained from
culture, empirical treatmentmust involve TMP—SMX, and the
treatment must be corrected as per antibiogram results,
because resistance to TMP—SMX has also been reported as
an increasing problem for this pathogen.18
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